Clinical Trial Update: A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD [Phase 4]

View source ↗

Summary

Phase 4 study of atomoxetine for attention deficit and hyperactive/impulsive behavior in children with autism spectrum disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Autism Spectrum Disorder

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED